The PennZone

  • Home
  • Business
  • Technology
  • Non-profit
  • Construction
  • Health
  • Real Estate
  • Travel
  • Legal

Lipella Pharmaceuticals Initiates Its Phase-2a Clinical Trial of LP-10 for Hemorrhagic Cystitis
The PennZone/10088711

Trending...
  • Ice Melts. Infrastructure Fails. What Happens to Clean Water?
  • When Representation No Longer Reflects the District — Why I'm Voting for Pete Verbica
  • The Legal AI Showdown: Westlaw, Lexis, ChatGPT… or EvenSteven?
PITTSBURGH--(BUSINESS WIRE)--Lipella Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on improving cancer survivorship, today announced it has begun recruiting patients in the company's phase 2a clinical trial to study the dose-dependent, safety and efficacy of LP-10 (liposomal tacrolimus) for the treatment of hemorrhagic cystitis.

"We are encouraged to be able to provide LP-10 to qualified patients," commented Jonathan Kaufman, Lipella's Chief Executive Officer. "Two clinical sites have started patient screening and recruitment, and we look forward to opening additional sites in the near future."

About Hemorrhagic Cystitis
Radiation used to treat prostate, colon, uterine, cervical and other pelvic cancers can cause chronic, painful urinary inflammation and blood loss called hemorrhagic cystitis. Certain chemotherapies (such as cyclophosphamide) can also cause this painful form of urinary bleeding. The blood loss, associated with hemorrhagic cystitis can lead to surgery, and can be fatal. There are currently no adequate therapies available for the treatment of moderate to severe hemorrhagic cystitis patients.

More on The PennZone
  • Cancun All Inclusive is ready for Spring Break 2026 with new Resorts, Exclusive Deals, activities and more!
  • 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies
  • Ludex Partners With Certified Trading Card Association (CTCA) To Elevate Standards And Innovation In The Trading Card Industry
  • Best Book Publishing Company for Aspiring Authors
  • Dr. Nadene Rose Releases Moving Memoir on Faith, Grief, and Divine Presence

About LP-10
LP-10 is a proprietary liposomal formulation of tacrolimus that is currently being evaluated as a treatment for moderate to severe hemorrhagic cystitis. Lipella Pharmaceuticals received FDA Orphan Designation for the use of tacrolimus for the treatment of hemorrhagic cystitis.

About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc. is a clinical stage pharmaceutical company with a focus on capital efficient therapeutic development opportunities, including the proprietary repositioning of generics for rare, morbid diseases that currently have no adequate treatments. Additional information is available at http://www.lipella.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause Lipella' results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors.

More on The PennZone
  • Gigasoft Solves AI's Biggest Charting Code Problem: Hallucinated Property Names
  • ASTI Ignites the Space Economy: Powering SpaceX's NOVI AI Pathfinder with Breakthrough Solar Technology: Ascent Solar Technologies (N A S D A Q: ASTI)
  • Hiring has reached a "Digital Stalemate"—Now, an ex-Google recruiter is giving candidates the answers
  • 2026 Pre-Season Testing Confirms a Two-Tier Grid as Energy Management Defines Formula 1's New Era
  • The Philadelphia Party Launches to Expand Civic Leadership, Candidate Pathways, and Education

Caution: LP-10 is currently not approved for commercial use in any indication in the United States and is limited by U.S. Federal Law to investigational use only.

Key words: hemorrhagic cystitis; radiation cystitis; phase-2a clinical trial; cancer survivorship; 505(b)(2) regulatory pathway; urinary bleeding; painful bladder; liposomal; drug; therapeutic; pharmaceutical
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Rocket Fibre Services Growing Customer Base With netElastic Networking Software
  • Cummings Graduate Institute for Behavioral Health Studies Honors New Doctor of Behavioral Health Graduates
  • IDpack v4 Launches: A Major Evolution in Cloud-Based ID Card Issuance
  • Corey Lakins Set to Launch Glow Your Influence, a Podcast Spotlighting Women Leaders
  • CCHR Says Psychiatry's Admission on Antidepressant Withdrawal Comes Far Too Late
  • 505 Plumbing, Heating & Cooling Launches in Albuquerque, Bringing a Customer-First Approach to Home Services
  • As AI.com Sells For Record $70 Million, Attention Now Turns To ArtificialIntelligence.com
  • AOW Event Sponsored By The Stanglwirt Resort a renowned five-star Austrian wellness destination
  • Average US gambler spends $210 per month in 2026
  • 10X Recruitment Launches Operator-Led Executive Search for Behavioral Health and Legal Leaders
  • Integris Composites developing armor for military in Arctic Circle
  • Caraline Skincare's Gentle Glow Cleansing Oil Named Finalist for Best Face Cleanser at the 2026 CertClean Clean Beauty Awards​
  • Workplace safety ideas from the front lines to highlight Applied Ergonomics Conference in Arlington, Texas
  • ThoroughCare Appoints New Chief Executive Officer & Chief Growth Officer to Accelerate Expansion
  • OpenSSL Corporation Advisory Committees' Elections 2026: Results Announcement
  • Zarova Vodka Expands Its Ultra-Premium Spirits Portfolio Through Strategic Acquisitions
  • The Legal AI Showdown: Westlaw, Lexis, ChatGPT… or EvenSteven?
  • François Arnaud, star of Heated Rivalry, is the real-life inspiration behind Christopher Stoddard's novel At Night Only
  • UK Financial Ltd Sets February 27 CATEX Debut for VENUS Coin, Opening Limited Early Access Through MayaPro Wallet
  • Ice Melts. Infrastructure Fails. What Happens to Clean Water?

Popular on PennZone

  • Michael Judkins Releases New Poetry Book, Deeper Than You Think
  • Still Using Ice? FrostSkin Reinvents Hydration
  • Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
  • OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors
  • Cold. Clean. Anywhere. Meet FrostSkin
  • Roshni Online Services Unveils Plans for Innovative Digital Consultation Platform
  • Luxury Lake-View Home Launches in Kissimmee's Bellalago community, Offering Privacy, Space, and Florida Resort-Style Living
  • Appliance EMT Partners with Kids Motel Ministry in Metro Atlanta
  • CNCPW Divulga Dados de Liquidez do 1º Trimestre: Confirma 100% de Reservas e Atualiza Protocolos de "Saque CNCPW" Contra Fluxos Ilícitos
  • Wala Blegay to Announce Run for Congress in Maryland's 5th District on Feb. 4

Similar on PennZone

  • Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth
  • Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
  • 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies
  • Ludex Partners With Certified Trading Card Association (CTCA) To Elevate Standards And Innovation In The Trading Card Industry
  • ASTI Ignites the Space Economy: Powering SpaceX's NOVI AI Pathfinder with Breakthrough Solar Technology: Ascent Solar Technologies (N A S D A Q: ASTI)
  • Hiring has reached a "Digital Stalemate"—Now, an ex-Google recruiter is giving candidates the answers
  • Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
  • Postmortem Pathology Expands Independent Autopsy Services in Kansas City
  • Postmortem Pathology Expands Independent Autopsy Services Across Colorado
  • $38 Million in U.S. Government Contract Awards Secured Through Strategic Partner. Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us